Barclays’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-27,000
| Closed | -$3.56M | – | 5659 |
|
|
2025
Q1 | $3.56M | Hold |
27,000
| – | – | ﹤0.01% | 2183 |
|
|
2024
Q4 | $2.26M | Buy |
+27,000
| New | +$2.22M | ﹤0.01% | 2789 |
|
|
2020
Q3 | – | Sell |
-20,000
| Closed | -$513K | – | 5662 |
|
|
2020
Q2 | $513K | Buy |
+20,000
| New | +$405K | ﹤0.01% | 3320 |
|
|
2020
Q1 | – | Sell |
-200
| Closed | -$7K | – | 6532 |
|
|
2019
Q4 | $7K | Buy |
+200
| New | +$2.4K | ﹤0.01% | 6146 |
|
|
2019
Q3 | – | Sell |
-62,500
| Closed | -$811K | – | 7209 |
|
|
2019
Q2 | $811K | Buy |
62,500
+33,800
| +118% | +$433K | ﹤0.01% | 3901 |
|
|
2019
Q1 | $350K | Buy |
28,700
+22,500
| +363% | +$288K | ﹤0.01% | 4406 |
|
|
2018
Q4 | $70K | Sell |
6,200
-16,900
| -73% | -$273K | ﹤0.01% | 5277 |
|
|
2018
Q3 | $501K | Hold |
23,100
| – | – | ﹤0.01% | 4280 |
|
|
2018
Q2 | $408K | Sell |
23,100
-21,600
| -48% | -$439K | ﹤0.01% | 4137 |
|
|
2018
Q1 | $941K | Buy |
44,700
+21,600
| +94% | +$421K | ﹤0.01% | 3292 |
|
|
2017
Q4 | $334K | Hold |
23,100
| – | – | ﹤0.01% | 4237 |
|
|
2017
Q3 | $365K | Buy |
+23,100
| New | +$339K | ﹤0.01% | 3902 |
|
|
2017
Q2 | – | Sell |
-9,800
| Closed | -$159K | – | 6994 |
|
|
2017
Q1 | $159K | Buy |
+9,800
| New | +$142K | ﹤0.01% | 4524 |
|
|
2016
Q4 | – | Sell |
-490,200
| Closed | -$7.47M | – | 6878 |
|
|
2016
Q3 | $7.47M | Buy |
490,200
+400,200
| +445% | +$16.2M | 0.01% | 1036 |
|
|
2016
Q2 | $3.49M | Buy |
+90,000
| New | +$3.23M | ﹤0.01% | 1572 |
|
|
2015
Q4 | – | Sell |
-44,400
| Closed | -$1.78M | – | 6677 |
|
|
2015
Q3 | $1.78M | Buy |
+44,400
| New | +$1.45M | ﹤0.01% | 2230 |
|
Other funds holding ITCI
Barclays's ITCI Position: Q2 2025 in Review
Barclays sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 49,003 shares — an estimated $6.46M sold.
Barclays first reported a position in ITCI in Q1 2014 and held it in 44 quarters. The position peaked at $14.9M in Q4 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Barclays reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Barclays sold 49,003 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.46M.
- Barclays first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 44 quarters.
- Barclays's Intra-Cellular Therapies Inc. position peaked at $14.9M in Q4 2023.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.